IAS News and Literature Updates:
January/February 2017
 From the President's Desk:
Yuji Matsuzawa

The IAS aims to provide current and relevant information about the diagnosis, treatment, and prevention of atherosclerotic cardiovascular disease.

The figure below shows the elements involved in the comprehensive risk management of atherosclerosis.

Since LDL cholesterol is a continuing major target both in familial hypercholesterolemia (FH) and non-FH hypercholesterolemia, we will continue to present practical strategies of effective cholesterol lowering treatments, including new drugs such as PCSK9 inhibitors.
> Complete Article < 


IAS Statin Publication Update Service

The International Atherosclerosis Society is very pleased to announce an exciting new and informative Newsletter for its membership: The IAS Statin Newsletter. The IAS, in partnership with Pfizer, will begin this month providing curated update on all publications involving statins as identified in PubMed. Statin publications have been targeted because of the fundamental role of statins as agents to reduce atherosclerotic cardiovascular disease (ASCVD) risk. The service aims to address the needs of health care professionals globally who manage patients with or at risk of developing ASCVD.  

                           IAS FH Activities                          

Launch e-learning
Improving management through genetic testing for Familial Hypercholesterolaemia (FH)

This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).

On completion of this e-learning you will have a better understanding of:

  • Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
  • How and why to use genetic testing
  • How to interpret results
  • How to use cascade screening to identify related individuals at risk
You can view the e-learning at http://www.cor2ed.com 
First Dyslipidemia and FH Clinic In Iraq

The establishment of the first dyslipidemia and FH clinic in Iraq by Dr. Mutaz Al-Sabah – a research, diagnostic and therapeutic center at the Al-Diwaniyah teaching hospital which will ultimately separate the FH clinic in the future as an independent center dealing with familial lipid disorders. Dr. Al-Sabah has also attended the first IAS-OSLA course on Lipid Metabolism and Cardiovascular Risk held in Muscat-Oman in February 2015 and has been a very active member of the IAS-OSLA Community since then.

                                                                                                                                        Link to the event photos

Also included in this newsletter:

Toronto, Canada
June 9 - 12, 2018

XVIII International Symposium on Atherosclerosis

In the News: 

Carotid Atherosclerosis and Stroke – From Bedside to Bench… And Back

By: L.P. Matic and U. Hedin

Cardiovascular disease (CVD) accounts for over 30% of global mortality, largely by complications of atherosclerosis such as myocardial infarction and ischemic stroke. Atherosclerosis leads to formation of plaques in the intima of major arteries with accumulation of lipids, inflammation, fibrosis, calcification, and cell apoptosis. Plaque instability is a dominating feature of complications to end-stage atherosclerosis and there are currently neither diagnostic methods nor pharmacotherapy available for prediction and prevention of plaque rupture.

> View Complete Commentary <

Understanding Bacterial Immunomodulation for the Treatment of Cardiovascular Diseases. Can We Learn From Bacteria?

By: V. Frodermann

In recent years we have come to appreciate the mutual benefits of bacterial commensalism. An example is the rapid developing field of the gut microbiome. We now know specific bacteria are crucial for the breakdown and synthesis of certain compounds, our gut microbiota is essential in fending off invading pathogens, and gut microbes can even instruct our immune system and thus directly affect our health. The development of the gut microbiome during early stages of life significantly shapes and affects the health of its host.

> View Complete Commentary <


March 11, 2017

Chilean Working Group on Atherosclerosis Course: Advances in the Treatment of Hypertension and Dyslipidemia
Antofagasta, Chile

Email: rodrigoalonsok@gmail.com

March 11-14, 2017

Immuno-Metabolic Mechanisms of Atherosclerosis: Novel Critical Mediators and Therapeutic Targets (IMMA 2017)
Cancun, Mexico

View Meeting Information

April 8, 2017

Chilean Working Group on Atherosclerosis Course: Advances in the Treatment of Hypertension and Dyslipidemia
Temuco, Chile

Email: rodrigoalonsok@gmail.com


The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA


You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2017 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile